ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), which happens to be one of the leading biopharmaceutical companies focusing on the commercialization as well as the development of the different targeted antiviral therapies, has today come forward to make the announcement regarding its planned move to develop a second-generation formulation of TXL™.
In a move to try and optimize its oral delivery, the provider is determined to kick-start its efforts to come up with a new formulation of TXL™. This particular strategy is as a matter of fact being utilized in a bid to try and boost the amount of TXL™ being delivered to the liver.
There are indeed high hopes that the new formulation of TXL™ will disregard the need to explore higher doses.
The Chief Medical Officer of ContraVir, John Sullivan-Bolyai in a press conference said, “Having established proof-of-principle with our first-generation formulation, we are excited to move forward with a second-generation formulation of TXL™, one that potentially delivers greater antiviral potency per dose. By providing enhanced drug delivery at a lower dose, the second-generation formulation offers the potential for once daily low dosing, thereby reducing the treatment burden for hepatitis B patients. The overriding goal for the new formulation is to facilitate combination therapy; an approach that we believe represents the future of anti-HBV therapy.”
It is important to highlight the fact that in as much as the advancement of a new formulation may seem quite a significant shift in the clinical development program, such a change in course might for sure present itself in the biopharmaceutical industry, whereby the emergence of a more advanced formulation of a drug candidate actually represents a clear pathway forward for the provider.
This came out clearly through a statement made by the Chief Executive Officer of ContraVir, James Sapirstein to news reporters when he said, “we expect the future treatment of HBV to be a combination of drugs, we are positioning TXL™ in such a way to drive down dosing and reduce the overall drug burden in patients.”
The future looks bright for the top company looking at the various developmental strategies it has been putting in place.
